Of the 2,045 patients in the study, 647 (32%) reported taking aspirin in addition to a prescribed DOAC, even though their medical history did not clearly indicate that need. Prof. Jordan Schaefer (University of Michigan, USA) compared 2 matched groups of 639 patients that had similar demographics, co-morbidities, and concurrent medications. Of the patients taking aspirin, the vast majority (90.3%) were taking low-dose aspirin (â€100 mg per day). Patients taking a DOAC alone had 261 319 bleeding events, compared with 319 261 bleeding events by those taking a DOAC plus aspirin; a 22% increase in bleeds over an average follow-up of 15 months. This difference was largely driven by clinically relevant non-major bleeding events, which were nearly 40% higher with dual therapy. Bleeding sites were most commonly bruising, intestinal bleeding, or bleeding through the urinary tract. Observed rates of thrombosis (stroke, VTE, and heart attacks) were similar between patients taking both medicines and those only on a DOAC (19 and 18 events, respectively).
The only 2 fatal bleeding events were seen among patients on DOACs only. Patients on dual therapy had more emergency room visits and hospitalisations mostly due to bleeding, but these differences did not reach statistical significance.
Prof. Schaefer said, âBased on our findings, adding aspirin may do more harm than good for some patients, increasing bleeding rates without improvements in the incidence of thrombosis.â He also indicated that he hopes these data will raise awareness within the medical community and lead to reducing the number of patients inappropriately taking aspirin.
1. Schaefer J, et al. Abstract 787, ASH 2019, 7-10 December, Orlando, USA.
Posted on
Previous Article
« Mild renal impairment in African Americans does not affect OS in AML Next Article
Adding daratumumab to carfilzomib/dexamethasone prolongs PFS and OS in R/R MM »
« Mild renal impairment in African Americans does not affect OS in AML Next Article
Adding daratumumab to carfilzomib/dexamethasone prolongs PFS and OS in R/R MM »
Table of Contents: ASH 2019
Featured articles
Late-Breaking Abstracts
Likely new standard of care: Blinatumomab for children with relapsed B-ALL
Pivotal phase 3 trial in cold agglutinin disease: sutimlimab can stop haemolysis
Oral azacitidine improves overall survival in patients with AML in remission
BCL11A as a novel target in gene therapy for sickle cell disease
Adding daratumumab to carfilzomib/dexamethasone prolongs PFS and OS in R/R MM
Long-term data of ropeginterferon alpha-2b in polycythaemia vera
Anti-CD70 is safe with hypomethylating agents in AML
MRD assessment to guide pre-emptive treatment decisions
Luspatercept effective for myelofibrosis-associated anaemia
Arsenic, ATRA, and ascorbic acid in acute promyelocytic leukaemia maintenance
Updated results ECOG-ACRIN E2906: decitabine maintenance after alloSCT
Sickle Cell Disease
Arginine supplements help against sickle cell disease pain
Abatacept prevents graft-versus-host disease in sickle cell patients after alloSCT
Plenary Scientific Session
HOVON-96: Better outcomes with cyclophosphamide after transplantation
Erythroferrone and skeletal changes associated with thalassaemia
Experimental model for limitations of haematopoietic stem cells propagation
Mosunetuzumab: complete remissions in non-Hodgkin lymphoma
Inclusive Medicine
Socioeconomic disparities and survival in paediatric AML
Oral selinexor/pomalidomide/dexamethasone shows activity in heavily pre-treated multiple myeloma
CAR T-cell therapy successful in older non-Hodgkinâs lymphoma patients
Mild renal impairment in African Americans does not affect OS in AML
ALCYONE: New overall survival results for myeloma
Venous Thromboembolism
Rivaroxaban is safe and effective for paediatric venous thromboembolism
Aspirin plus DOAC is not better than a DOAC alone
20-Year follow-up of imatinib in chronic myeloid leukaemia after failure with interferon
CAR T and Beyond
BCMA-targeted CAR T therapy yields 100% response in relapsed/refractory MM
Anti-BCMA/anti-CD38 in refractory multiple myeloma
Related Articles
October 20, 2021
Some young people who undergo HCT retain ability to conceive
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com